Table 2. Associations of discharge prescription for spironolactone with outcomes at 30 days post-discharge among Medicare beneficiaries hospitalized for heart failure with ejection fraction <45% and estimated glomerular filtration rate <45 mL/min/1.73m2.
| % (total events / total patients) Spironolactone on discharge | Hazard ratio†(95% CI); p-value | |||
|---|---|---|---|---|
|
| ||||
| No | Yes | Unadjusted | Propensity score adjusted | |
| All-cause readmission | 25% (237/933) | 30% (61/207) | 1.19 (0.90–1.57); p=0.233 | 1.41 (1.04–1.90); p=0.027 |
| Heart failure readmission | 12% (116/933) | 12% (25/207) | 0.97 (0.63–1.49); p=0.872 | 0.90 (0.57–1.41); p=0.635 |
| All-cause mortality | 8% (75/933) | 8% (17/207) | 1.01 (0.60–1.72); p=0.961 | 1.05 (0.60–1.82); p=0.866 |
| All-cause mortality or readmission | 31% (285/933) | 34% (70/207) | 1.13 (0.87–1.47); p=0.352 | 1.31 (0.99 –1.73); p=0.058 |
†
Hazard ratios comparing patients receiving spironolactone on discharge with those not receiving it